hyaluronan + gemcitabine

**HA + gemcitabine** (also known as hyaluronan-gemcitabine or HyACT-gemcitabine) is a tumor-targeted formulation of the chemotherapeutic drug gemcitabine combined with hyaluronic acid (HA). Developed primarily under Alchemia's proprietary HyACT® (Hyaluronic Acid ChemoTransport) platform, this formulation utilizes HA as a targeting vehicle to selectively deliver gemcitabine to CD44-overexpressing cancer cells, including cancer stem cells (CSCs). CD44 is a cell-surface glycoprotein that is highly expressed on various solid tumors and serves as a key marker for CSCs, which are often resistant to standard chemotherapy. By binding to CD44, the HA-gemcitabine formulation is internalized via receptor-mediated endocytosis, enhancing intracellular drug accumulation and cytotoxicity while potentially reducing systemic side effects. Preclinical studies have demonstrated its efficacy in breast cancer, pancreatic cancer, glioblastoma, and lung cancer models.

Other names

HA + gemcitabineHA-GEMHA-gemcitabineHA/GemcitabineHyACT-gemcitabinehyaluronan-gemcitabine